Quick Takeaways: Why It Matters? ECO’s licence of Vaxinano’s late‑stage sheep toxoplasmosis vaccine gives it a low‑cost, de‑risked way to add a high‑value preventative product that directly tackles a major cause of abortion and lamb losses, with peak sales estimated a...
Quick Takeaways: Why It Matters? Boehringer Ingelheim’s purchase of Evax gives it a promising new way to treat common horse allergies with longer‑lasting vaccines instead of short‑term symptom relief, which could mean fewer vet visits and better outcomes for owners. If the approach works a...
Quick Takeaways: Why It Matters? Zoetis’ EC approval of Poulvac Procerta HVT-ND turns its single-dose, dual ND+Marek’s protection into a mainstream EU option, which should drive rapid adoption as producers shift from multi-vaccine schedules to a streamlined, in‑ovo or hatch-day protocol th...
Quick Takeaways: Why It Matters? ECO Animal Health’s EU launch of Ecovaxxin MS is a meaningful commercial milestone because it converts the company’s own R&D pipeline into a marketed product and gives it a differentiated position in poultry vaccines. With access to a market spanning mo...
Quick Takeaways: Why It Matters? Elanco is tightening its premium position in canine vaccines by launching the first 0.5 mL combo shot that covers both Lyme disease and leptospirosis in a single, low-volume dose, using its PureFil technology to support fewer reactions and more co...
Quick Takeaways: Why It Matters? Ceva is using this deal to cement a differentiated position in swine health by owning Europe’s only commercial vaccine against swine dysentery, a disease that drives major losses in pig production. This will also deepen Ceva’s R&D pipeline and...
Quick Takeaways: Why It Matters? Lenzelta gives Boehringer Ingelheim a next‑generation mastitis vaccine that fits neatly into dry‑off protocols: two intramuscular doses in late gestation deliver early‑onset immunity and up to six months...
Artificial Intelligence (AI) and digital diagnostics are rapidly reshaping veterinary medicine, introducing new possibilities for earlier disease detection, faster decision-making, and more personalized care for animals. As veterinary clinics and research institutions embrace technological...
Quick Takeaways: Why It Matters? The USDA’s positive safety verdict for Ecovaxxin MG significantly de‑risks US registration, validating ECO’s live‑strain platform and setting up a clear path toward a 2027 filing in a large Mycoplasma gallisepticum market.&nb...
